Intarcia seeks FDA nod for Medici drug delivery system
Intarcia Therapeutics said today that it submitted a New Drug Application to the FDA for its injection-free ITCA 650 candidate, the 1st drug to use Intarcia’s Medici drug delivery system to treat Type II diabetes. The ITCA 650 enables subcutaneous delivery of exenatide using a match-sized osmotic pump placed under the skin in an in-office procedure. With the NDA submission, the Boston-based company triggered a 3rd, $100 million milestone payment from the $300 million royalty financing put in place in the 2nd quarter of 2015. The milestone payment adds to the $215 million Intarcia raised in Se...
Source: Mass Device - November 21, 2016 Category: Medical Equipment Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Implants Pharmaceuticals Regulatory/Clearance Intarcia Therapeutics Source Type: news

Expensive New Diabetes Drugs Add Nothing But Cost And Complications
This is the fourth in an ongoing series of blogs exposing the rampant misuse of the medications so aggressively promoted by greedy drug companies. I am very lucky in having the perfect partner in this truth-vs-power effort to contradict Pharma propaganda with evidence based fact. Dick Bijl is President of the International Society of Drug Bulletins (ISDB), an impressive association of 53 national drug bulletins from all around the world, each of which publishes the best available data on the pluses and minuses of different medications. Drug bulletins help patients and doctors see through the misleading misinformation ge...
Source: Science - The Huffington Post - November 17, 2016 Category: Science Source Type: news

Exenatide Disappoints in Cardiac Arrest Exenatide Disappoints in Cardiac Arrest
The GLP-1 analog had no effect on a marker of neurological injury, but there was a hint of a possible reduction in mortality, in a new study.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 12, 2016 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes First Data on GLP-1 Agonist/SGLT2 Inhibitor Combo in Diabetes
Exenatide once weekly combined with daily dapagliflozin improved glycemic outcomes, BP, and weight loss more than each drug alone in DURATION-8, the first trial to examine a combination of these 2 agents.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 20, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Intarcia raises another $215m to support its ITCA 650 drug pump
Intarcia Therapeutics said today it raised $215 million in a new round of financing to support the approval and launch of its ITCA 650 implantable drug pump, designed for treating type 2 diabetes, which the company has slated to launch in late 2017. The Cambridge, Mass.-company said it expects a “larger second close with additional top-tier investors” in the 4th quarter. Intarcia is looking to raise up to $600 million by the end of the year to support the approval and launch of the device, according to a report from the Boston Business Journal. The ITCA 650 implantable drug pump is a matchst...
Source: Mass Device - September 15, 2016 Category: Medical Equipment Authors: Fink Densford Tags: Business/Financial News Diabetes Drug Pumps Intarcia Therapeutics Source Type: news

Teva, AstraZeneca settle patent dispute over multimillion-dollar drug
Teva Pharmaceuticals USA Inc. said Thursday it has settled patent litigation with AstraZeneca Pharmaceuticals and Amylin Pharmaceuticals that involved the prescription medicine Byetta. Byetta is an injectable drug used to improve blood sugar control in adults with type 2 diabetes. The drug generated revenues of $316 million for AstraZeneca in 2015. Under the terms of the settlement, AstraZeneca (NYSE: AZN) granted a license to Teva (NYSE: TEVA) to manufacture and commercialize the generic version… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 23, 2016 Category: Pharmaceuticals Authors: John George Source Type: news

Subdermal mini-pump with exenatide superior to sitagliptin in reducing HbA1c
NEW ORLEANS – The second trial involving a sub-dermal matchstick-size osmotic mini-pump that releases exenatide over 6 months in people who have poorly controlled type 2 diabetes achieved superior... (Source: Clinical Endocrinology News)
Source: Clinical Endocrinology News - June 12, 2016 Category: Endocrinology Source Type: news

Intarcia raises another $75m, touts top-line safety data in pivotal trial
Intarcia Therapeutics said today that it raised another $75 million in a debt financing round and touted the top-line cardiovascular safety data from the final phase in its clinical program for its ITCA 650 implantable drug pump for Type II diabetics. Boston-based Intarcia said it plans to begin filing for U.S. approval from the FDA during the 3rd quarter, now that the safety data is in from its 4,000-patient Freedom-CVO trial. The debt financing, a new credit facility with MidCap Financial and Silicon Valley Bank, is slated for scaling up its manufacturing for the ITCA 650, the company said. The device...
Source: Mass Device - May 6, 2016 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Food & Drug Administration (FDA) Funding Roundup Regulatory/Compliance Intarcia Therapeutics Source Type: news

Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients
A type 2 diabetes treatment has been found to also have 'off-label' benefits for glucose control in the liver and in fatty cells known as adipose. The study shows that exenatide, a treatment that targets the pancreas to improve glucose absorption, enhances glucose uptake and reduces insulin resistance in the liver and in adipose tissue. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 15, 2016 Category: Science Source Type: news

Additional benefits of type 2 diabetes treatment found for non-alcoholic fatty liver disease patients
(European Association for the Study of the Liver) A type 2 diabetes treatment has been found to also have 'off-label' benefits for glucose control in the liver and in fatty cells known as adipose. Presented at The International Liver CongressTM 2016 in Barcelona, Spain, today, the study shows that exenatide, a treatment that targets the pancreas to improve glucose absorption, enhances glucose uptake and reduces insulin resistance in the liver and in adipose tissue. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 15, 2016 Category: Infectious Diseases Source Type: news

Could a diabetes drug help beat concaine addiction?
A study by sceintists at the Unviersity of Pensylvania found that common diabetes drug Byetta plays a rule in concaine consumption. The study was published in Neuropsychopharmacology. Daily Mail (Source: Society for Endocrinology)
Source: Society for Endocrinology - February 12, 2016 Category: Endocrinology Source Type: news

Diabetes drug found to help beat cocaine addiction
Scientists from University of Pennsylvania discovered that Byetta, a diabetes drug that targets a hormone dealing with food consumption, can also decrease an addict's desire for cocaine. (Source: the Mail online | Health)
Source: the Mail online | Health - February 12, 2016 Category: Consumer Health News Source Type: news

New approach offered to treating cocaine addiction
An FDA-approved drug used for diabetes and obesity may also reduce cocaine dependence, new research indicates. The drug, trade name Byetta, derives from a naturally occurring hormone called glucagon-like peptide-1, or GLP-1, which regulates feeding behavior. Knowing what they did about GLP-1, the research team turned to it as a possible treatment for cocaine addicts. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 11, 2016 Category: Science Source Type: news

Glide Technologies Announces Successful Proof-of-Concept with Novel Exenatide Solid Dose Formulation
Glide Technologies has announced that they have successfully completed a pre-clinical proof-of-concept study with its novel solid dose formulation of exenatide, a GLP-1 agonist for the treatment of Type 2 diabetes. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 27, 2016 Category: Pharmaceuticals Source Type: news

Some Differences Between Once-Weekly GLP-1 AgonistsSome Differences Between Once-Weekly GLP-1 Agonists
Once-weekly GLP-1 receptor agonists dulaglutide, exenatide, and the now-withdrawn taspoglutide show the greatest reduction of HbA1c in a meta-analysis. Hypoglycemia risk is similar across the class. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 9, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Once-a-week diabetes meds are similar in safety and effectiveness
(In this Nov 8 story, corrects name of Bydureon in paragraph 10 from Byetta.) (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2015 Category: Consumer Health News Tags: healthNews Source Type: news

Weekly GLP-1RAs Compared for Type 2 Diabetes (FREE)
By Kelly Young Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Dulaglutide, once-weekly exenatide, and taspoglutide are associated with the largest reductions in hemoglobin A1c among all the weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), according to a network meta-analysis … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 8, 2015 Category: Primary Care Source Type: news

Data Support Twice Yearly Exenatide 'Minipump' for DiabetesData Support Twice Yearly Exenatide 'Minipump' for Diabetes
An investigational subdermal device that delivers the GLP-1 agonist exenatide for 6 to 12 months in patients with type 2 diabetes reduced HbA1c and lowered weight in phase 3 studies. Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 29, 2015 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Implantable Exenatide Delivery Device Lowers HbA1c in T2DMImplantable Exenatide Delivery Device Lowers HbA1c in T2DM
The rationale behind the subcutaneous drug-delivery platform is to offer patients an alternative to regular life-long injections and improve patient compliance and convenience, according to study investigators. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2015 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

MassDevice.com +3 | The top 3 medtech stories for August 19, 2015
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.   3. Masimo takes over Tony Stark’s headquarters Masimo moved its headquarters to a Hollywood-hotspot at 52 Discovery in Irvine, Calif., a location often used in films to represent upscale corporate headquarters. The rotund glass front entrance has served as a backdrop for multiple Hollywood ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: MassDevice Tags: Blog Plus 3 Source Type: news

Diabetes: Intarcia’s implantable drug pump tops Merck’s Januvia
Intarcia Therapeutics yesterday unveiled top-line results from a year-long trial of an implantable drug pump for Type II diabetics, saying its ITCA 650 treatment proved superior to its comparator, Merck‘s (NYSE:MRK) Januvia. Fifty-two week results from the Phase III Freedom-2 trial met all primary and secondary endpoints, “demonstrating superiority over Januvia at every measured time point,” Intarcia said. The matchstick-sized, miniature osmotic pump reduced glycated hemoglobin (HbA1c) levels and weight in patients in the study, the company said. The subcutaneous ITCA 650 is ...
Source: Mass Device - August 19, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Clinical Trials Diabetes Drug Pumps Intarcia Therapeutics newtag Source Type: news

Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its...
Delpor has exclusive rights to the patented technology and has several product candidates in development, including 3-6 month formulations of exenatide, liraglutide, and basal insulin.(PRWeb April 23, 2015)Read the full story at http://www.prweb.com/releases/2015/04/prweb12671977.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 24, 2015 Category: Pharmaceuticals Source Type: news

Byetta, Victoza, Bydureon: Diabetes drugs and weight loss
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - April 11, 2015 Category: Consumer Health News Source Type: news

Real-world usage and cost of exenatide and liraglutide
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2015 Category: Drugs & Pharmacology Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
Hundreds of Byetta lawsuits and other product liability claims involving incretin mimetic diabetes drugs are currently pending in the federal litigation underway in California.(PRWeb December 21, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12409444.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 22, 2014 Category: Pharmaceuticals Source Type: news

Diabetes Drug Litigation Prepares to Discuss Byetta Lawsuits, Claims...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 07, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12376827.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 7, 2014 Category: Pharmaceuticals Source Type: news

New Order Issued in Federal Incretin Mimetic Litigation, Where...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer caused by incretin mimetic...(PRWeb December 01, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12363707.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 2, 2014 Category: Pharmaceuticals Source Type: news

California Federal Court Overseeing Byetta Lawsuits, Other Incretin...
The Firm is evaluating Byetta lawsuits and other product liability claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer after taking incretin...(PRWeb November 23, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12344447.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 23, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Plaintiffs in Federal Diabetes Drug Litigation...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb November 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12318604.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 13, 2014 Category: Pharmaceuticals Source Type: news

Diabetes Drug Claims Near 550 Mark in Incretin Mimetic Litigation,...
The Firm is investigating Byetta lawsuits and other legal claims that allege pancreatic cancer, pancreatitis and thyroid cancer caused by incretin mimetics, a Type 2 diabetes drug class.(PRWeb November 02, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12294498.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 2, 2014 Category: Pharmaceuticals Source Type: news

Delpor Awarded $220K NIH Grant for 3-month Exenatide Implant for the...
The NIDDK funds Delpor’s efforts to utilize its NANOPOR technology in developing a matchstick-size subcutaneous implant device capable of delivering exenatide for 3-12 months through passive diffusion(PRWeb October 17, 2014)Read the full story at http://www.prweb.com/releases/2014/10/prweb12247910.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 17, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits and other legal claims that allege the use of diabetes drugs called incretin mimetics caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb October 08, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12234584.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 9, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, With New Ruling Issued in Federal...
The Firm is evaluating Byetta lawsuits and other product liability claims that allege incretin mimetic diabetes drugs caused patients to develop pancreatic cancer, pancreatitis and thyroid cancer.(PRWeb September 24, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12196939.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 25, 2014 Category: Pharmaceuticals Source Type: news

AstraZeneca's Phase III trial of diabetes drug exenatide meets primary endpoint
AstraZeneca has reported positive results from its Phase III trial (DURATION-NEO-1) of exenatide to treat adult patients with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - September 22, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Issued in Federal Incretin Mimetics...
The Firm is evaluating Byetta lawsuits on behalf of individuals who developed pancreatitis, pancreatic cancer or thyroid cancer allegedly due to their use of Byetta or other incretin mimetic Type 2...(PRWeb September 11, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12163899.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 12, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes...
The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer due to their use of the medication.(PRWeb August 30, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12133359.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 30, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: Bernstein Liebhard LLP Notes British...
The Firm is actively investigating Januvia and Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and other serious injuries after taking either of the...(PRWeb August 15, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12098941.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 16, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit News: New Order Establishes Deposition Protocol For...
The Firm is investigating Byetta lawsuits and other legal claims that allege incretin mimetics like Byetta, Januvia and Victoza caused patients to develop pancreatic cancer, pancreatitis or thyroid...(PRWeb August 10, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb12083571.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - August 10, 2014 Category: Pharmaceuticals Source Type: news

AstraZeneca reports positive results from extension of DURATION-1 trial of Bydureon
AstraZeneca has reported positive results from the extension of the DURATION-1 trial of exenatide for treatment of patients with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - June 17, 2014 Category: Pharmaceuticals Source Type: news

AstraZeneca's Bydureon achieves better glycaemic control than insulin glargine in type 2 diabetes
UK-based AstraZeneca has reported results from its longest, randomised, head-to-head DURATION-3 trial of exenatide once-weekly, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type 2 diabetes in adult patients uncontrolle… (Source: Drug Development Technology)
Source: Drug Development Technology - June 2, 2014 Category: Pharmaceuticals Source Type: news

Featured in NEJM Journal Watch: Incretin-Based Diabetes Drugs Aren't Associated with Excess Risk for Acute Pancreatitis (FREE)
Extract Although not the final word, results of two large studies in BMJ should be reassuring for patients taking exenatide (Byetta) and sitagliptin (Januvia... (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 8, 2014 Category: Primary Care Source Type: news

Exenatide has potential as disease modifying agent in Parkinson's disease
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 6, 2014 Category: Science Source Type: news

Exenatide's Effect on Beta-cell Function in New Onset T2DMExenatide's Effect on Beta-cell Function in New Onset T2DM
Does daily GLP-1 receptor agonist use improve beta-cell function? Clinical Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - April 3, 2014 Category: Endocrinology Tags: Diabetes & Endocrinology Journal Article Source Type: news

AstraZeneca obtains FDA approval for Bydureon Pen to treat type 2 diabetes
AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bydureon Pen (exenatide extended-release for injectable suspension) 2mg as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 dia… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - March 5, 2014 Category: Pharmaceuticals Source Type: news

FDA Approves Pen Form of Extended-Release ExenatideFDA Approves Pen Form of Extended-Release Exenatide
A new product contains the same formulation and dosing of current extended-release exenatide but eliminates the need for filling a syringe. FDA Approvals (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 3, 2014 Category: Consumer Health News Tags: Medscape Today News Alert Source Type: news

FDA Approves Bydureon Pen
(MedPage Today) -- The FDA has approved a new means of delivery for weekly exenatide (Bydureon) - a pen formulation - for patients with type 2 diabetes. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 3, 2014 Category: Cardiology Source Type: news

Incretin-Targeting Diabetic Drugs: FDA & EMA See No Apparent Pancreatic Harms (FREE)
By Joe Elia Drugs targeting the insulin-releasing effects of the hormone incretin, such as exenatide (Byetta) and sitagliptin (Januvia), cause no apparent increase in pancreatic side effects, according to a … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - February 28, 2014 Category: Primary Care Source Type: news

Byetta Lawsuit Plaintiff Withdraws Motion Seeking Consolidation of...
The Firm is evaluating Byetta lawsuits on behalf of patients who allegedly developed pancreatic cancer, pancreatitis, or thyroid cancer due to their use of the Type 2 diabetes medication.(PRWeb February 22, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11608217.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 22, 2014 Category: Pharmaceuticals Source Type: news

Byetta Lawsuit Update: Court Considering Case Management Proposals in...
The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, thyroid cancer or pancreatitis, allegedly due to their use of the Type 2 diabetes medication.(PRWeb February 17, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11587413.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 17, 2014 Category: Pharmaceuticals Source Type: news

As Byetta Lawsuits Move Forward, Bernstein Liebhard LLP Notes New FDA...
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic...(PRWeb February 13, 2014)Read the full story at http://www.prweb.com/releases/byetta-lawsuit/byetta-pancreatic-cancer/prweb11583185.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - February 14, 2014 Category: Pharmaceuticals Source Type: news